Coronary aneurysm after implantation of a paclitaxel-eluting stent

Scandinavian Cardiovascular Journal

Volumn 38, Issue 6, 2004, Pages 349-352

  Vik Mo, Harald ^a   Wiseth, Rune ^a   Hegbom, Knut ^a  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

Coronary aneurysm; Drug eluting stent; Intravascular ultrasound; Paclitaxel; Stent malapposition

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; EPTIFIBATIDE; HEPARIN; PACLITAXEL; SIMVASTATIN;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR DISEASE; CASE REPORT; CORONARY ARTERY ANEURYSM; CORONARY STENT; DRUG ELUTING STENT; ECHOCARDIOGRAPHY; HUMAN; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; TRANSLUMINAL CORONARY ANGIOPLASTY;

ADULT; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ANEURYSM; CORONARY RESTENOSIS; DRUG DELIVERY SYSTEMS; HUMANS; MALE; PACLITAXEL; POLYMERS; STENTS;

EID: 12344293250     PISSN: 14017431     EISSN: None     Source Type: Journal    
DOI: 10.1080/14017430410016413     Document Type: Article

References (19)

1. Serruys PW, Degertekin M, Tanabe K, et al. for the RAVEL Study Group. Intravascular ultrasound findings in the multicenter, randomized, double-blind RAVEL (Randomized study with the sirolimus-eluting velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery Lesions) trial. Circulation 2002; 106: 798-803.
2. Tanabe K, Serruys PW, Degertekin M, et al. for the TAXUS II Study Group. Chronic arterial responses to polymer-controlled paclitaxel-eluting stents: Comparison with bare metal stents by serial intravascular ultrasound analyses: Data from the randomized TAXUS-II trial. Circulation 2004; 109: 196-200.
3. Morice MC, Serruys PW, Sousa JE, et al. for the RAVEL Study Group. A randomized cornpatison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-1780.
4. Moses JW, Leon MB, Popma JJ, et al. for the SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-1323.
5. Stone GW, Ellis SG, Cox DA, et al. for the TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221-231.
6. Tanabe K, Serruys PW, Grube E, et al. TAXUS III trial. In-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation 2003; 107: 559-564.
7. Sousa JE, Costa MA, Sousa AGMR, et al. Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries. Circulation 2003; 107: 381-383.
8. Bullesfeld L, Gerckens U, Muller R, Grube E. Long-term evaluation of paclitaxel-coated stents for treatment of native coronary lesions. First results of both the clinical and angiographic 18 month follow-up of TAXUS I. Z Kardiol 2003; 92: 825-832.
9. Farb A, Heller PF, Shroff S, et al. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation 2001; 104: 473-479.
10. Heldman AW, Cheng L, Jenkins GM, et al. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation 2001; 103: 2289-2295.
11. van der Giessen WJ, Lincoff M, Schwartz RS, et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 1996; 94: 1690-1697.
12. Curcio A, Torella D, Cuda G, et al. Effect of stent coating alone on in vitro vascular smooth muscle cell proliferation and apoptosis. Am J Physiol Heart Circ Physiol 2004; 286: H902-H908.
13. Degertekin M, Serruys PW, Tanabe K, et al. Long-term follow-up of incomplete stent apposition in patients who received sirolimus-eluting stent for de novo coronary lesions: An intravascular ultrasound analysis. Circulation 2003; 108: 2747-2750.
14. Virmani R, Guagliumi G, Farb A, et al. Localized hypersensitivity and coronary thrombosis secondary to a sirolimus-eluting stent. Should we be more cautious? Circulation 2004; 109: 701-705.
15. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med 1995; 332: 1004-1014.
16. Baumbach A, Herdeg C, Kluge M, et al. Local drug delivery: Impact of pressure, substance characteristics, and stenting on drug transfer into arterial wall. Cathet Cardiovasc Intervent 1999; 47: 102-106.
17. Drachman DE, Edelman ER, Seifert P, et al. Neointimal thickening after stent delivery of paclitaxel: Change in composition and arrest of growth over six months. J Am Coll Cardiol 2000; 36: 2325-2332.
18. Liistro F, Stankovic G, Di Mario C, et al. First clinical experience with a paclitaxel derivate-eluting polymer stent system implantation for in-stent restenosis: Immediate and long-term clinical and angiographic outcome. Circulation 2002: 1883-1886.
19. Virmani R, Liistro F, Stankovic G, et al. A mechanism of late in-stent restenosis after implantation of paclitaxel derivate-eluting stent system in humans. Circulation 2002; 106: 2649-2651.